BioHarvest

Functional Biofood Production

Agriculture & Food Technologies
Acquired by CannaVcell Sciences on Apr, 2020

Company Overview

Snapshot

Founded in January 2007 by Zaki Rakib and Yochi Hagay, BioHarvest operates with 11–50 employees. The company has raised a total of $13.37 million across 7 funding rounds from 2 investors. In November 2024, BioHarvest Sciences began trading on the Nasdaq Global Market.

Business overview

BioHarvest develops technology to produce functional biofood, ensuring optimal bioavailability and efficacy of plant phytochemicals in their natural state. Its flagship product, VINIA, is a red grape powder offering the benefits of red wine without alcohol or sugar. The company utilizes a clean hydroponic production process free of solvents, GMOs, and chemical residues. BioHarvest also applies its biofarming technology to produce cannabinoids without growing the cannabis plant itself, serving the Agriculture & Food Technologies sector and contributing to sustainable farming practices by minimizing energy, water, and land usage.

Strategic signal

In November 2024, BioHarvest Sciences began trading on the Nasdaq Global Market. This uplisting signifies a major validation of the company's market presence and growth trajectory, providing enhanced visibility and access to a broader investor base. For investors, this move suggests increased liquidity and potential for future capital appreciation, reflecting confidence in BioHarvest's innovative biofood and cannabinoid production technologies.

Company Intelligence Q&A

What was a significant recent market event for BioHarvest?
In November 2024, BioHarvest Sciences began trading on the Nasdaq Global Market, marking a significant milestone for the company.
When did BioHarvest announce a private placement of up to $5 million?
In June 2024, BioHarvest Sciences announced a private placement of up to USD $5 million.
What was a key development in BioHarvest's cannabis cell reservoir technology?
In July 2021, BioHarvest Sciences Inc.'s first cannabis cell reservoir demonstrated the ability to produce ongoing flowering stage cannabinoid cells for two years.
What was the outcome of BioHarvest's acquisition by CannaVcell Sciences?
BioHarvest was acquired by CannaVcell Sciences in April 2020. This transaction was a business combination with its controlling shareholder.
What was a notable early clinical result for VINIA?
In March 2016, BioHarvest Ltd. announced preliminary clinical results of VINIA on Type 2 Diabetes.

External links